Switch to:
Also traded in: Australia, Germany, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash-to-Debt No Debt
PRAN's Cash-to-Debt is ranked higher than
90% of the 610 Companies
in the Global Biotechnology industry.

( Industry Median: 49.39 vs. PRAN: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
PRAN' s Cash-to-Debt Range Over the Past 10 Years
Min: 16.62  Med: No Debt Max: No Debt
Current: No Debt
Equity-to-Asset 0.93
PRAN's Equity-to-Asset is ranked higher than
91% of the 483 Companies
in the Global Biotechnology industry.

( Industry Median: 0.63 vs. PRAN: 0.93 )
Ranked among companies with meaningful Equity-to-Asset only.
PRAN' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.73  Med: 0.88 Max: 0.99
Current: 0.93
0.73
0.99
Interest Coverage No Debt
PRAN's Interest Coverage is ranked higher than
93% of the 485 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. PRAN: No Debt )
Ranked among companies with meaningful Interest Coverage only.
PRAN' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 2
Altman Z-Score: 2.11
Beneish M-Score: 15.33
WACC vs ROIC
1.13%
-282.65%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -9394.37
PRAN's Operating Margin % is ranked lower than
92% of the 503 Companies
in the Global Biotechnology industry.

( Industry Median: -50.65 vs. PRAN: -9394.37 )
Ranked among companies with meaningful Operating Margin % only.
PRAN' s Operating Margin % Range Over the Past 10 Years
Min: -9561.58  Med: -2433.66 Max: -168.18
Current: -9394.37
-9561.58
-168.18
Net Margin % -5443.66
PRAN's Net Margin % is ranked lower than
91% of the 503 Companies
in the Global Biotechnology industry.

( Industry Median: -43.94 vs. PRAN: -5443.66 )
Ranked among companies with meaningful Net Margin % only.
PRAN' s Net Margin % Range Over the Past 10 Years
Min: -5405.59  Med: -2522.12 Max: -167.86
Current: -5443.66
-5405.59
-167.86
ROE % -21.73
PRAN's ROE % is ranked higher than
53% of the 544 Companies
in the Global Biotechnology industry.

( Industry Median: -24.74 vs. PRAN: -21.73 )
Ranked among companies with meaningful ROE % only.
PRAN' s ROE % Range Over the Past 10 Years
Min: -175.24  Med: -94.62 Max: -15.33
Current: -21.73
-175.24
-15.33
ROA % -20.32
PRAN's ROA % is ranked higher than
52% of the 616 Companies
in the Global Biotechnology industry.

( Industry Median: -21.99 vs. PRAN: -20.32 )
Ranked among companies with meaningful ROA % only.
PRAN' s ROA % Range Over the Past 10 Years
Min: -139.67  Med: -72.71 Max: -14.1
Current: -20.32
-139.67
-14.1
ROC (Joel Greenblatt) % -285.29
PRAN's ROC (Joel Greenblatt) % is ranked lower than
52% of the 585 Companies
in the Global Biotechnology industry.

( Industry Median: -218.94 vs. PRAN: -285.29 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
PRAN' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -21719.66  Med: -5534.89 Max: -387.23
Current: -285.29
-21719.66
-387.23
3-Year Revenue Growth Rate -100.00
PRAN's 3-Year Revenue Growth Rate is ranked lower than
94% of the 435 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. PRAN: -100.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
PRAN' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -30.7 Max: 152
Current: -100
0
152
3-Year EBITDA Growth Rate 2.80
PRAN's 3-Year EBITDA Growth Rate is ranked higher than
52% of the 469 Companies
in the Global Biotechnology industry.

( Industry Median: 1.30 vs. PRAN: 2.80 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
PRAN' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -20.3 Max: 28.3
Current: 2.8
0
28.3
3-Year EPS without NRI Growth Rate -13.30
PRAN's 3-Year EPS without NRI Growth Rate is ranked lower than
62% of the 459 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. PRAN: -13.30 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
PRAN' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -12.95 Max: 71
Current: -13.3
0
71
GuruFocus has detected 3 Warning Signs with Prana Biotechnology Ltd $PRAN.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» PRAN's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-08-27)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

PRAN Guru Trades in

PRAN Guru Trades in

Q3 2016

PRAN Guru Trades in Q3 2016

Jim Simons 19,217 sh (New)
» More
Q4 2016

PRAN Guru Trades in Q4 2016

Jim Simons 16,295 sh (-15.21%)
» More
» Details

Insider Trades

Latest Guru Trades with PRAN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology  
Compare:NAS:MBVX, OTCPK:SRBCF, NAS:BVXV, OTCPK:BRTX, AMEX:CVM, NAS:CBLI, OTCPK:MRNA, NAS:TENX, NAS:OGXI, NAS:ACST, OTCPK:OBMP, NAS:CYCC, OTCPK:OPNT, OTCPK:RGIN, NAS:VTGN, NAS:SBOT, NAS:ABIO, NAS:CYAN, NAS:GNVC, NAS:APTO » details
Traded in other countries:PBT.Australia, PBNN.Germany, PRNAF.USA,
Prana Biotechnology Ltd is engaged in the development of therapeutic drugs designed to treat the causes of degeneration of the brain as the aging process progresses including Alzheimer's disease, Huntington's disease and Parkinson's disease.

Prana Biotechnology Ltd was incorporated on November 11, 1997. The Company is a development stage company at an early stage in the development of its pharmaceutical products. The Company's activities include research into Alzheimer 's disease and other age-related degenerative disorders. Its compound PBT2, is manufactured by Dr. Reddys based in Hyderabad, India. It competes with pharmaceutical companies, biotechnoloy firms, universities and research institutions. The Company is subject to governmental laws and regulations.

Ratios

vs
industry
vs
history
PB Ratio 0.85
PRAN's PB Ratio is ranked higher than
93% of the 556 Companies
in the Global Biotechnology industry.

( Industry Median: 3.85 vs. PRAN: 0.85 )
Ranked among companies with meaningful PB Ratio only.
PRAN' s PB Ratio Range Over the Past 10 Years
Min: 0.65  Med: 6.72 Max: 34.32
Current: 0.85
0.65
34.32
EV-to-EBIT 0.10
PRAN's EV-to-EBIT is ranked higher than
98% of the 196 Companies
in the Global Biotechnology industry.

( Industry Median: 18.89 vs. PRAN: 0.10 )
Ranked among companies with meaningful EV-to-EBIT only.
PRAN' s EV-to-EBIT Range Over the Past 10 Years
Min: -53.7  Med: -4.4 Max: 1
Current: 0.1
-53.7
1
EV-to-EBITDA 0.10
PRAN's EV-to-EBITDA is ranked higher than
99% of the 213 Companies
in the Global Biotechnology industry.

( Industry Median: 16.23 vs. PRAN: 0.10 )
Ranked among companies with meaningful EV-to-EBITDA only.
PRAN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -53.9  Med: -4.5 Max: 1
Current: 0.1
-53.9
1
Current Ratio 14.28
PRAN's Current Ratio is ranked higher than
90% of the 585 Companies
in the Global Biotechnology industry.

( Industry Median: 3.45 vs. PRAN: 14.28 )
Ranked among companies with meaningful Current Ratio only.
PRAN' s Current Ratio Range Over the Past 10 Years
Min: 4.11  Med: 6.39 Max: 15.35
Current: 14.28
4.11
15.35
Quick Ratio 14.28
PRAN's Quick Ratio is ranked higher than
90% of the 583 Companies
in the Global Biotechnology industry.

( Industry Median: 3.24 vs. PRAN: 14.28 )
Ranked among companies with meaningful Quick Ratio only.
PRAN' s Quick Ratio Range Over the Past 10 Years
Min: 4.11  Med: 6.39 Max: 15.35
Current: 14.28
4.11
15.35
Days Sales Outstanding 12.00
PRAN's Days Sales Outstanding is ranked higher than
86% of the 405 Companies
in the Global Biotechnology industry.

( Industry Median: 62.87 vs. PRAN: 12.00 )
Ranked among companies with meaningful Days Sales Outstanding only.
PRAN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.85  Med: 157.02 Max: 13449.32
Current: 12
0.85
13449.32

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -11.80
PRAN's 3-Year Average Share Buyback Ratio is ranked lower than
53% of the 503 Companies
in the Global Biotechnology industry.

( Industry Median: -10.60 vs. PRAN: -11.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
PRAN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -144.7  Med: -17.15 Max: 0
Current: -11.8
-144.7
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 1.00
PRAN's Price-to-Net-Cash is ranked higher than
97% of the 295 Companies
in the Global Biotechnology industry.

( Industry Median: 7.38 vs. PRAN: 1.00 )
Ranked among companies with meaningful Price-to-Net-Cash only.
PRAN' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.07  Med: 7.25 Max: 43
Current: 1
1.07
43
Price-to-Net-Current-Asset-Value 0.84
PRAN's Price-to-Net-Current-Asset-Value is ranked higher than
98% of the 387 Companies
in the Global Biotechnology industry.

( Industry Median: 6.60 vs. PRAN: 0.84 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
PRAN' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.07  Med: 6.5 Max: 43
Current: 0.84
1.07
43
Price-to-Tangible-Book 0.85
PRAN's Price-to-Tangible-Book is ranked higher than
95% of the 494 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. PRAN: 0.85 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
PRAN' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.64  Med: 6.76 Max: 42.16
Current: 0.85
0.64
42.16
Earnings Yield (Greenblatt) % 1000.00
PRAN's Earnings Yield (Greenblatt) % is ranked higher than
100% of the 639 Companies
in the Global Biotechnology industry.

( Industry Median: -6.50 vs. PRAN: 1000.00 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
PRAN' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 104.2  Med: 156.8 Max: 316.4
Current: 1000
104.2
316.4

More Statistics

Revenue (TTM) (Mil) $0.10
EPS (TTM) $ -0.64
Beta0.56
Short Percentage of Float2.24%
52-Week Range $1.52 - 6.69
Shares Outstanding (Mil)8.90

Analyst Estimate

Jun17
Revenue (Mil $)
EPS ($) -0.03
EPS without NRI ($) -0.03
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for PRAN

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
Prana AGM investor webcast details Nov 13 2016
Prana receives $4.8 million R&D Tax Incentive Cash Refund Oct 30 2016
New Data from Reach2HD Trial Presented at American Neurological Association Annual Meeting Oct 18 2016
New Data from Reach2HD Trial Presented at American Neurological Association Annual Meeting Oct 18 2016
New Data from Reach2HD Trial Presented at American Neurological Association Annual Meeting Oct 18 2016
ANA Abstract Submission NLP Oct 17 2016
PRANA BIOTECHNOLOGY LTD Financials Oct 08 2016
Annual Report filed on Form 20-F with SEC Oct 04 2016
Prana Alzheimer's disease data features at world leading conference Jul 27 2016
Prana Alzheimer's disease data features at world leading conference Jul 27 2016
Five Stocks on the Move Today Amid a Mixed Market Jun 22 2016
Prana Regains Compliance with NASDAQ Continued Listing Requirements Continues to Work Towards FDA... Apr 11 2016
Prana Regains Compliance with NASDAQ Continued Listing Requirements Continues to Work Towards FDA... Apr 11 2016
Prana Biotechnology Half Year Investor Report Feb 26 2016
Prana Biotechnology Half Year Investor Report Feb 26 2016
US STOCKS-S&P 500 ends at record as jobs report eases Fed worries Sep 05 2014
US STOCKS-S&P 500 ends at record as jobs report eases Fed worries Sep 05 2014
US STOCKS-Wall St rises as weak payrolls ease Fed worries Sep 05 2014
US STOCKS-Wall St rises as weak payrolls ease Fed worries Sep 05 2014
US STOCKS-Wall St flat following weak payrolls report Sep 05 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)